Protagenic Therapeutics Inc. Announces Corporate Restructuring, Shifts to Virtual Operating Model and Streamlines Focus on Key Clinical Program
Reuters
Aug 14
<a href="https://laohu8.com/S/PTIX">Protagenic Therapeutics Inc</a>. Announces Corporate Restructuring, Shifts to Virtual Operating Model and Streamlines Focus on Key Clinical Program
Protagenic Therapeutics Inc. has announced a strategic reorganization to enhance its operational focus and financial efficiency. The company's Board of Directors approved a Restructuring Plan on August 8, 2025, shifting towards a virtual operating model to prioritize its highest-priority clinical program. This plan includes suspending expenditures on preclinical programs and exploring strategic alternatives for these assets, such as partnerships or out-licensing. The company aims to reduce annual operating expenses by approximately $8 million and has already begun reducing headcount, including the elimination of several executive roles. Protagenic is concentrating its resources on executing the Phase 2 clinical trial of PT00114, expected to conclude within 9 to 12 months.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagenic Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-023588), on August 13, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.